Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  C R Bard Inc    BCR

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

BARD(CR) : Bard Announces Agreement to Acquire Medivance, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/25/2011 | 10:15pm CEST

C. R. Bard, Inc. (NYSE: BCR) today announced that it has reached a definitive agreement to acquire Medivance, Inc. for a purchase price of approximately $250 million. The transaction will be structured as a merger subject to the satisfaction of customary conditions, including Hart-Scott-Rodino clearance. Upon completion of the merger, the Medivance organization will become part of Bard Medical division.

Medivance, located in Louisville, Colorado, is the market leader in the field of therapeutic hypothermia. In recent years, accurate manipulation of body temperature to targeted levels has emerged as an effective treatment option for a variety of critically ill patients. The American Heart Association, The American Stroke Association, The Brain Trauma Foundation and various international medical associations have issued therapeutic hypothermia guidelines as the clinical data supporting Targeted Temperature Management? has grown. Medivance's Arctic Sun® family of products provides clinicians with a powerful technology to effectively manage patient temperature in a non-invasive manner.

Timothy M. Ring, chairman and CEO, commented, "With their unique and proprietary technology, Medivance is the market leader in an emerging and growing space. This merger is a great strategic fit for Bard as Medivance's Targeted Temperature Management? product line is synergistic with our critical care sales call point, and their technology efficiently addresses a large unmet need in a market that is growing double digits. This acquisition represents an important building block for our critical care product offering."

Based on the anticipated completion of the merger in the fourth quarter of 2011, Bard expects the dilution impact to be immaterial to earnings per share in 2011.

C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current expectations, the accuracy of which is necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as "anticipate", "estimate", "expect", "project", "intend", "forecast", "plan", "believe", and other words of similar meaning in connection with any discussion of future operating or financial performance. Many factors may cause actual results to differ materially from anticipated results including product developments, sales efforts, income tax matters, the outcomes of contingencies such as legal proceedings, and other economic, business, competitive and regulatory factors. The company undertakes no obligation to update its forward-looking statements. Please refer to the Cautionary Statement Regarding Forward-Looking Information in our June 30, 2011 Form 10-Q for more detailed information about these and other factors that may cause actual results to differ materially from those expressed or implied.

C. R. Bard, Inc.
Investor Relations:
Todd W. Garner, 908-277-8065
Vice President, Investor Relations
or
Media Relations:
Scott T. Lowry, 908-277-8365
Vice President and Treasurer


© Business Wire 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on C R BARD INC
12:11p C R BARD : Technical Reports on Medical Supplies Stocks -- Endologix, Becton, Di..
03/22 Global Catheter Stabilization Device Market- C. R. Bard, Smiths Medical, 3M, ..
03/17 Synthetic Peptide Market 2017 - Pfizer, Meyer-Haake, OptMed, C.R. Bard, GluSt..
03/16 C R BARD : Global Surgical Mesh Market- Atrium, B. Braun Melsungen AG, Ethicon I..
03/09 C R BARD : Patent Issued for Multiple Imaging Mode Tissue Marker (USPTO 9579077)
03/07 C R BARD : Bard to Present at Barclays Global Healthcare Conference
02/27 C R BARD : Bard to Present at Cowen and Company Healthcare Conference
02/23 INSIDER TRADING ACTIVITY C R BARD IN : BCR) – Insider Sold 4,390 shares of..
02/14 INSIDER TRADING ACTIVITY C.R. BARD, : BCR) – VP Sold 3,292 shares of Stoc..
02/13 C R BARD : BARD C R INC /NJ/ Management's Discussion and Analysis of Financial C..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
03/28DJMEDTRONIC : Files 8K - Entry Into Definitive Agreement
03/28DJMEDTRONIC : Files 8K - Entry Into Definitive Agreement
03/22DJMEDTRONIC : Files 8K - Other Events
03/17DJMEDTRONIC : Less-Invasive Treatment Yielded Similar Outcome as Open-Heart Surger..
03/11DJLUXOTTICA : Smart Glasses Get a Fresh Look -- WSJ
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
03/27 UPDATE : Portfolio123 Designer Low Volatility Portfolio
03/05 DIVIDEND INCOME UPDATE : February 2017
02/12 INSIDERINSIGHTS.COM DAILY ROUND UP 2 : Ty, arnc, celh
02/03 Tracking Yacktman Asset Management Portfolio - Q4 2016 Update
01/27 C. R. Bard's (BCR) CEO Timothy Ring on Q4 2016 Results - Earnings Call Transc..
Advertisement
Financials ($)
Sales 2017 3 889 M
EBIT 2017 1 117 M
Net income 2017 815 M
Debt 2017 19,9 M
Yield 2017 0,42%
P/E ratio 2017 23,79
P/E ratio 2018 20,77
EV / Sales 2017 4,65x
EV / Sales 2018 4,39x
Capitalization 18 055 M
More Financials
Chart C R BARD INC
Duration : Period :
C R Bard Inc Technical Analysis Chart | BCR | US0673831097 | 4-Traders
Full-screen chart
Technical analysis trends C R BARD INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 249 $
Spread / Average Target -0,09%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Tim M. Ring Chairman & Chief Executive Officer
John H. Weiland President, Chief Operating Officer & Director
Christopher S. Holland Chief Financial Officer & Senior Vice President
John A. DeFord Senior VP-Science, Technology & Clinical Affairs
Patricia G. Christian VP-Quality, Regulatory & Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
C R BARD INC11.14%18 055
MEDTRONIC PLC13.91%111 071
BAXTER INTERNATIONAL I..17.23%28 171
ZIMMER BIOMET HOLDINGS..17.61%24 408
HOYA CORPORATION10.55%19 065
DENTSPLY SIRONA INC9.02%14 456
More Results